前列腺癌中激素依赖(ADPC)和非依赖型(AIPC)的诊断和区分治疗，给临床带来诸多困难。若能找到可同时靶向并杀伤两种分型的给药系统，将给前列腺癌的治疗带来新的革命。本课题拟在前期研究ADPC给药基础上，选择可同时靶向两种ADPC/AIPC型前列腺癌细胞(LNCaP,PC-3)表面CD71受体的第三代适体C2min为靶头，阳离子聚合物聚酰胺胺(PAMAM)为载体，包裹可抑制两种癌细胞存活、增殖的基因药物siR-M，以双功能聚乙二醇(NHS-PEG-MAL)作为桥接，首次构建适体-聚乙二醇-聚酰胺胺载siR-M：[C2min-PEG-PAMAM/siR-M] 双重靶向全程杀伤纳米给药系统，并探讨其调控LNCaP和PC-3增殖作用机理，胞内转运、降解机制及体内分布特征。该同时可靶向两种分型前列腺癌的新型单靶头纳米基因递释系统的构建及作用机制研究，国内外尚未报道，可为前列腺癌治疗方案开辟新途径。

Diagnosis and separate treatments of hormone-dependent treatment (ADPC) and nonhormone-dependent (AIPC) in prostate cancer have brougt plenty of problems to clinical practices. If we can find a drug delivery system that can simultaneously target and kill these two kinds of PCa , that will be a new revolution in the treatment of PCa.This project, based on preliminary studies on ADPC administration , selected a single (LNCaP and PC-3) surface CD71 receptor generation the aptamer C2min to target head cationic polymerization matter Polyamidoamine (PAMAM), which can be targeted to these two prostate cancer cells (ADPC / AIPC), as the carrier, wrapping SIR-M which can inhibit both cancer survivals, gene proliferations , through the dual function as bridging polyethylene glycol (NHS-PEG-MAL), building aptamer - polyethylene glycol - polyamidoamine contained siR-M: [C2min-PEG-PAMAM/siR-M] single-stage target header dual targeted full anti-nanometer administration system, and to elucidate its mechanism of regulation of LNCaP and PC-3 proliferation intracellular transporters, degradation mechanisms and in vivo distribution characteristics. Through this research, we plan to build a new single-stage target head dually targeting the full killing of the two parting PCa nano drug delivery system, opening new avenues for optimizing PCa treatment options.